Tresiba

Tresiba (insulin degludec) is an ultra-long-acting basal insulin analog with a duration of action of more than 42 hours, providing once-daily basal coverage with greater dosing flexibility than older 24-hour insulins. Approved in 2015 for adults and later expanded to children age 1 and older, Tresiba is available in two strengths — U-100 FlexTouch pens and U-200 FlexTouch pens — and is widely used in both type 1 and type 2 diabetes.

Tresiba belongs to the Long-Acting Insulin Analogs class. After subcutaneous injection, degludec self-assembles into soluble multi-hexamer chains in the subcutaneous depot, slowly releasing insulin monomers over >42 hours. The resulting flat, ultra-long profile reduces nocturnal hypoglycemia compared to insulin glargine U-100 in head-to-head trials.

## What Tresiba is used for

Tresiba is indicated for glycemic control in type 1 and type 2 diabetes in adults and children age 1 and older. It is typically used as the basal component of a basal-bolus regimen in type 1 diabetes and either as basal monotherapy or combined with oral agents or a GLP-1 receptor agonist in type 2 diabetes.

## Dosage and how to use the Tresiba FlexTouch pen

Tresiba is injected subcutaneously once daily. Because of its >42-hour duration, the time of day is flexible — pick a time that fits your routine and stick to it for consistency. Rotate sites between abdomen, thigh, and upper arm.

• Insulin-naive type 2: start 10 units once daily.
• Switching from once-daily basal (Lantus, Basaglar, Toujeo, Levemir once daily): unit-for-unit start.
• Switching from twice-daily basal: start at 80% of total daily basal.
• Titration: adjust every 3–4 days to a fasting glucose target (typically 80–130 mg/dL).

The U-100 FlexTouch pen dials 1–80 units in 1-unit increments. The U-200 FlexTouch pen dials 2–160 units in 2-unit increments — read the displayed dose carefully so you do not double or halve your intended units.

## Side effects of Tresiba

Common: hypoglycemia, injection-site reactions, weight gain, peripheral edema, and upper respiratory tract infection. Serious: severe hypoglycemia, hypokalemia, and anaphylactic allergic reactions. Rare: lipodystrophy with poor site rotation.

Long-term side effects of Tresiba in real-world data are consistent with other insulins; the most important to discuss with your prescriber are unexplained weight gain, recurrent hypoglycemia, and persistent injection-site reactions.

## Managing common side effects

• Hypoglycemia: carry rapid glucose (tablets or juice). Family should know how to administer glucagon.
• Weight gain: maintain dietary and activity habits; discuss a GLP-1 agonist add-on if appropriate.
• Injection-site reactions: rotate sites systematically across the abdomen and thighs.

## Tresiba vs Lantus, Toujeo, Basaglar, Levemir

• Tresiba vs Lantus: Tresiba duration >42 hr vs Lantus ~24 hr. Tresiba allows more flexibility in timing and has reduced nocturnal hypoglycemia in clinical trials.
• Tresiba vs Toujeo: Both are ultra-long. Toujeo is glargine U-300; Tresiba is degludec. Comparable A1c reductions; subtle differences in hypoglycemia and peakiness.
• Tresiba vs Basaglar/Lantus biosimilars: Tresiba has longer duration and slightly higher acquisition cost.
• Tresiba vs Levemir: Levemir often requires twice-daily dosing for full coverage; Tresiba is once-daily.
• Tresiba and Victoza: combined available as Xultophy (degludec/liraglutide).

## Tresiba conversion calculator

When switching: - Lantus → Tresiba (once-daily): unit-for-unit start. - Toujeo → Tresiba: unit-for-unit; monitor for hypoglycemia given more potent Tresiba profile. - Twice-daily basal → Tresiba: 80% of total daily basal.

Always titrate based on fasting glucose after switching.

## Cost, savings card, and patient assistance

Cash price ranges approximately $400–$600 per box without insurance. The Tresiba Savings Card can lower eligible commercially insured patient cost to as low as $99 for a 90-day supply; the Novo Nordisk Patient Assistance Program (PAP) provides free product for qualifying low-income uninsured patients; Medicare's $35/month insulin cap also applies. Search for Tresiba manufacturer coupon, Tresiba copay card, Tresiba savings card activation, Tresiba discount card, or discount coupons for Tresiba for the latest programs.

## How long does Tresiba take to work?

Tresiba begins lowering glucose within a few hours but reaches steady state after 3–4 days of consistent dosing. Because of its long half-life, titration must be slow — wait at least 3–4 days between dose changes.

## Drug interactions

Sulfonylureas, meglitinides, other insulins, and GLP-1 agonists all increase hypoglycemia risk when combined with Tresiba. Beta-blockers mask hypoglycemia warning symptoms. Thiazolidinediones combined with insulin may worsen heart failure. Alcohol potentiates hypoglycemia.

## Monitoring and lifestyle

Monitor fasting glucose for titration, HbA1c every 3–6 months, and kidney function periodically. Review sick-day insulin adjustments. Continuous glucose monitoring (CGM) is particularly helpful with ultra-long basal insulins to detect overnight trends.

## Storage and travel

Unopened: refrigerate at 2–8°C. In-use Tresiba pens or vials may be kept at room temperature (≤30°C) for up to 56 days — among the longest in-use windows of any insulin, useful for travel. Do not freeze. Avoid direct sunlight.

## Use in specific populations

Pregnancy: Insulin remains the preferred glucose-lowering therapy; degludec data are increasing and supportive. Breastfeeding: Compatible. Children: Approved from age 1. Older adults: Use simpler regimens and lower starting doses to reduce hypoglycemia risk.

## Key takeaways

• Tresiba is an ultra-long-acting basal insulin with >42-hour duration of action.
• Once-daily dosing with flexible timing — pick a consistent time when possible.
• Reduced nocturnal hypoglycemia compared to Lantus in head-to-head trials.
• U-100 and U-200 FlexTouch pens — confirm which pen you have before dosing.
• In-use pens are stable at room temperature for 56 days.

## Medical disclaimer

This article about Tresiba (insulin degludec) is for general education and is not a substitute for professional medical advice, diagnosis, or treatment. Always follow the guidance of your physician or pharmacist and the instructions on your prescription label.